Autobio Diagnostics Co., Ltd. (SHA:603658)

Market Cap	17.79B -24.6%
Revenue (ttm)	4.22B -2.3%
Net Income	994.14M -13.2%
EPS	1.72 -13.9%
Shares Out	571.42M
PE Ratio	18.07
Forward PE	16.45
Dividend	1.31 (4.01%)
Ex-Dividend Date	Jun 1, 2026

Volume	2,351,960
Open	32.25
Previous Close	32.13
Day's Range	31.04 - 32.25
52-Week Range	28.18 - 41.89
Beta	-0.02
Analysts	Buy
Price Target	38.19 (+22.64%)
Earnings Date	Aug 25, 2026

About Autobio Diagnostics

Autobio Diagnostics Co., Ltd. engages in the research and development, production, marketing, sale, and service of clinical diagnostic products in China and internationally. The company offers immunoassay, biochemistry, and microbiology products; reagents and instruments; and technical and support, and training services, as well as engages in biology research and development activities. Its immunoassay products consist of AutoLumo S900 and AutoLumo A1860 that provides user experience for small and medium size labs; AutoLumo A6200/A6600, an auto...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1998
• Employees: 5,700
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603658

Financial Performance

In 2025, Autobio Diagnostics's revenue was 4.23 billion, a decrease of -5.47% compared to the previous year's 4.47 billion. Earnings were 1.07 billion, a decrease of -10.59%.

Analyst Summary

According to 5 analysts, the average rating for 603658 stock is "Buy." The 12-month stock price target is ¥38.19, which is an increase of 22.64% from the latest price.

Price Target

¥38.19

(22.64% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 11, 2026

Data Sources Report a data error